Prostate Cancer - Results from #100

Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer. December 4, 2024

Surgical and oncological outcomes of salvage radical prostatectomy after focal therapies: a matched-pair analysis. December 4, 2024

Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients. December 4, 2024

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. December 4, 2024

Prostate cancer in people with HIV. December 4, 2024

Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review. December 4, 2024

Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment. December 3, 2024

ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer. December 3, 2024

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors. December 3, 2024

Preoperative Briganti Nomogram Score and Risk of Prostate Cancer Progression After Robotic Surgery Beyond EAU Risk Categories. December 3, 2024

Adipose Tissues Have Been Overlooked as Players in Prostate Cancer Progression. December 3, 2024

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. December 2, 2024

Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function. December 2, 2024

Gene-based burden tests of rare germline variants identify six cancer susceptibility genes. December 2, 2024

Germline sequence variation in cancer genes in Rwandan breast and prostate cancer cases. December 2, 2024

Hugo™ Versus daVinci™ Robot-Assisted Radical Prostatectomy: 1-Year Propensity Score-Matched Comparison of Functional and Oncological Outcomes. December 2, 2024

Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogramming. November 29, 2024

Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer. November 29, 2024

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm. November 29, 2024

Active surveillance follow-up for prostate cancer: from guidelines to real-world clinical practice. November 29, 2024

Page 6 of 1447